Schering/GSK Levitra Labeling Drops Alpha Blocker Contraindication
This article was originally published in The Pink Sheet Daily
Executive Summary
Alpha blocker/PDE-5 inhibitor contraindication in vardenafil labeling is downgraded to precaution; the language is identical to a recent revision for Lilly’s Cialis. References on concomitant use with alpha blockers are now on par with Cialis and Pfizer’s Viagra.
You may also be interested in...
Cialis Sheds Alpha Blocker Contraindication
Lilly/Icos’ erectile dysfunction agent revises labeling to include a new subsection on alpha blockers within the Precautions section, but no contraindication. Schering Plough/GlaxoSmithKline’s Levitra is now the only PDE5 inhibitor with the contraindication.
Bayer Seeking Levitra Label Without Alpha Blocker Contraindication
Second quarter sales for Levitra were lower than expected, hampered by a slow erectile dysfunction market, the company says. Bayer remains optimistic about long-term Levitra sales growth despite competition from Pfizer and Lilly.
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.